Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials

Area of Science:

• Cardiology
• Pharmacology

Background:

• The comparative benefit-risk profile of bivalirudin versus heparin anticoagulation in non-ST-segment-elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI) remains uncertain.
• Previous meta-analyses lacked the granularity to provide definitive conclusions.

Approach:

• An individual patient data meta-analysis was conducted using data from 5 large trials (MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY, BRIGHT).
• The analysis included 12,155 patients randomized to either bivalirudin or heparin, focusing on 30-day all-cause mortality and serious bleeding as primary endpoints.

Key Points:

• Thirty-day mortality rates were similar between bivalirudin (1.2%) and heparin (1.1%) groups (aOR, 1.24; P=0.25).
• No significant differences were observed in cardiac mortality, reinfarction, or stent thrombosis rates between the two anticoagulants.
• Bivalirudin significantly reduced serious bleeding events, both access site-related and non-access site-related, compared to heparin (3.3% vs 5.5%; aOR, 0.59; P<0.0001).

Conclusions:

• Procedural anticoagulation with bivalirudin or heparin in NSTEMI patients undergoing PCI yields comparable rates of mortality and ischemic events.
• Bivalirudin demonstrates a significant safety advantage by reducing serious bleeding complications compared to heparin.